Hybio Pharmaceutical Co., Ltd. (SHE:300199)
China
· Delayed Price · Currency is CNY 20.98
-1.12 (-5.07%)
Apr 29, 2026, 3:04 PM CST
Hybio Pharmaceutical Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Apr '26 Apr 28, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | 2021 - 2017 |
| Market Capitalization | 19,520 | 15,810 | 11,385 | 11,994 | 15,527 | 11,138 | Upgrade
|
| Market Cap Growth | 41.12% | 38.87% | -5.08% | -22.75% | 39.41% | 88.22% | Upgrade
|
| Enterprise Value | 21,326 | 17,616 | 13,122 | 13,710 | 17,024 | 12,784 | Upgrade
|
| Last Close Price | 22.10 | 17.90 | 12.89 | 13.58 | 17.58 | 12.61 | Upgrade
|
| PE Ratio | - | 432.32 | - | - | - | 361.52 | Upgrade
|
| Forward PE | - | 9.21 | 9.21 | 9.21 | 9.21 | 9.21 | Upgrade
|
| PS Ratio | 21.73 | 16.36 | 19.29 | 27.80 | 22.05 | 15.13 | Upgrade
|
| PB Ratio | 29.31 | 25.10 | 19.07 | 15.31 | 11.97 | 6.76 | Upgrade
|
| P/TBV Ratio | 51.95 | 45.03 | 39.92 | 22.37 | 15.44 | 8.43 | Upgrade
|
| P/FCF Ratio | 151.45 | - | 232.96 | - | - | - | Upgrade
|
| P/OCF Ratio | 56.20 | 67.59 | 69.12 | - | 982.28 | 71.02 | Upgrade
|
| PEG Ratio | - | 0.73 | 0.73 | 0.73 | 0.73 | 0.73 | Upgrade
|
| EV/Sales Ratio | 23.75 | 18.23 | 22.23 | 31.78 | 24.17 | 17.37 | Upgrade
|
| EV/EBITDA Ratio | 83.10 | 50.27 | 115.59 | - | - | - | Upgrade
|
| EV/EBIT Ratio | 190.41 | 80.61 | - | - | - | - | Upgrade
|
| EV/FCF Ratio | 165.46 | - | 268.51 | - | - | - | Upgrade
|
| Debt / Equity Ratio | 3.03 | 3.03 | 3.01 | 2.59 | 1.39 | 1.09 | Upgrade
|
| Debt / EBITDA Ratio | 5.43 | 5.43 | 15.72 | - | - | - | Upgrade
|
| Debt / FCF Ratio | - | - | 36.79 | - | - | - | Upgrade
|
| Net Debt / Equity Ratio | 2.87 | 2.87 | 2.85 | 2.15 | 1.19 | 0.71 | Upgrade
|
| Net Debt / EBITDA Ratio | 5.15 | 5.15 | 14.99 | -7.57 | -29.27 | -8.09 | Upgrade
|
| Net Debt / FCF Ratio | -4012.74 | -4012.74 | 34.83 | -19.76 | -8.85 | -27.80 | Upgrade
|
| Asset Turnover | 0.31 | 0.31 | 0.19 | 0.13 | 0.19 | 0.19 | Upgrade
|
| Inventory Turnover | 1.61 | 1.61 | 1.44 | 1.52 | 1.12 | 1.58 | Upgrade
|
| Quick Ratio | 0.14 | 0.14 | 0.14 | 0.36 | 0.52 | 1.28 | Upgrade
|
| Current Ratio | 0.29 | 0.29 | 0.33 | 0.48 | 0.71 | 1.55 | Upgrade
|
| Return on Equity (ROE) | 5.55% | 5.55% | -26.10% | -49.56% | -25.30% | 1.71% | Upgrade
|
| Return on Assets (ROA) | 4.43% | 4.43% | -0.64% | -6.74% | -3.03% | -4.26% | Upgrade
|
| Return on Invested Capital (ROIC) | 4.74% | 4.89% | -1.36% | -14.00% | -6.44% | -7.61% | Upgrade
|
| Return on Capital Employed (ROCE) | 15.90% | 15.90% | -2.00% | -20.00% | -7.40% | -8.50% | Upgrade
|
| Earnings Yield | -0.35% | 0.23% | -1.52% | -4.28% | -2.39% | 0.28% | Upgrade
|
| FCF Yield | 0.66% | -0.00% | 0.43% | -0.71% | -1.12% | -0.38% | Upgrade
|
| Payout Ratio | - | 259.33% | - | - | - | 375.37% | Upgrade
|
| Buyback Yield / Dilution | -2.67% | -5.29% | 2.00% | -0.42% | 14.09% | -11.21% | Upgrade
|
| Total Shareholder Return | -2.67% | -5.29% | 2.00% | -0.42% | 14.09% | -11.21% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.